Joseph R. Mikhael, MD

Panelist discusses the current acceleration of new therapies for multiple myeloma. In the future, oncologists will be able to use CAR T and bispecific therapies more efficiently, and they will also have new tools including new CAR T therapies and bispecifics that will require less manufacturing time, have fewer AEs, and be more effective regarding the targeted disease.

Panelist discusses how every drug oncologists use comes with adverse events (AEs), and with bispecifics they are seeing a similar AE profile to that seen in CAR T-cell therapy. There are 3 major AEs: cytokine release syndrome, neurological toxicity, and infections. To manage AEs, oncologists are now monitoring patients more intensely as well as engaging with the patient’s family to provide updates on the status of the patient.

Panelist discusses how bispecifics have had a major impact in relapsed/refractory multiple myeloma (R/R MM) because they provide a different way of attacking myeloma, allow oncologists an opportunity to care for patients who cannot have CAR T therapy, and allow oncologist to treat patients who have had an aggressive relapse. The panelist further discusses the importance of bispecifics dosing specifically to maintain a response with the drug but also to prevent the risk of patient infection.

The panel closes their discussion by highlighting crucial takeaways about the use of bispecific antibodies in the treatment of multiple myeloma.

Doctors discuss the potential of bispecific therapies being used in earlier lines of treatment for multiple myeloma, and the need for understanding and reducing toxicities as much as possible.

Experts explain the strategies for optimal selection between different BCMA-targeting and non-BCMA-targeting bispecifics for the treatment of relapsed/refractory multiple myeloma.

Cindy Varga, MD, details her experience with sequencing BCMA-targeting agents for patients with relapsed/refractory multiple myeloma.

Jeremy Larsen, MD, discusses the management of infections, neurotoxicity, and other side effects associated with bispecifics in patients with R/R MM, including the need for prophylactic antimicrobials and monitoring of immunoglobulin levels.

Expert panelists in multiple myeloma share their experiences with implementing bispecifics and transition of care in the community setting for patients with R/R MM.

The panel discusses the approach to step-up and treatment dosing for bispecifics in their respective health care systems.

Expert hematologist-oncologists discuss how they incorporate teclistamab in their clinical practice as well as variations in access to bispecifics and CAR T-cell therapy.

Jeremy Larsen, MD, discusses data from a phase 1/2 study of cevostamab and other emerging bispecifics being evaluated in patients with relapsed/refractory multiple myeloma.

Dr Jeremy Larsen reviews data from the MonumenTAL-1 study investigating the CD3- and GPRC5D-targeting bispecific antibody talquetamab in relapsed/refractory multiple myeloma.

Dr Cindy Varga discusses recent data on the FDA-approved agent teclistamab, a bispecific antibody for patients with relapsed/refractory multiple myeloma.

Binod Dhakal, MD, MS, discusses the management of relapsed multiple myeloma and the various treatment options available.

Dr Joseph Mikhael and Dr Hakan Kaya provide advice for community oncologists who use selinexor and discuss the future of selinexor in patients with R/R MM.

Teclistimab and similar bispecifics can have a prolific impact on patients with heavily relapsed multiple myeloma in the short term and possibly in earlier relapses in the long term, according to Joseph Mikhael, MD.

Joseph Mikhael, MD, discussed the need for increased diversity in clinical trials, specifically in the hematology space.

Two experienced clinicians share their thoughts on the safety of selinexor, including how they optimize dosing to prioritize patient comfort.

Dr Mikhael and Dr Kaya discuss the clinical implications and share their thoughts on the use of selinexor, carfilzomib and dexamethasone in patients with R/R MM.

Joseph Mikhael, MD, in a conversation on important presentations from the 2022 International Myeloma Society Annual Meeting, highlighted key findings with lenalidomide plus RVd and stem cell transplant in patients with high-risk multiple myeloma.

Dr Mikhael reviews the baseline characteristics, study design and key efficacy and safety data of selinexor, carfilzomib, dexamethasone (XKd) in patients with relapsed/refractory multiple myeloma who are non-refractory to carfilzomib.

Joseph Mikhael, MD, provides a brief overview of the relapsed/refractory multiple myeloma landscape and explains the mechanism of action of selinexor.

Joseph Mikhael, MD, spoke about the mechanism of action of bispecific antibody teclistamab relative to other agents in the space such monoclonal antibodies and CAR T-cell therapies in multiple myeloma.

In this video, Dr. Mikhael discusses the current treatment paradigm for multiple myeloma and highlights some of the new agents in development.